CTLA4 and neoplasm: The observed differences in immune checkpoint proteins like PDL1 and CTLA4 indicate greater impedance of anti-tumor immunity in the high AMPAO group, consistent with prior studies linking PDL1 expression to poor prognosis and immunotherapy response in HNSCC.